Combined MAO-A (rs1137070, rs2072743, rs66323) and MAO-B (rs1799836, rs2283729) Homozygosity Report

By Dan Purser MD

Genomic Architecture and Dual-Enzyme Pathophysiology

Monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) are outer mitochondrial membrane-bound enzymes critical for the oxidative deamination of biogenic amines, catecholamines, and dietary monoamines. MAO-A preferentially degrades serotonin (5-HT), norepinephrine, and epinephrine, while MAO-B primarily catabolizes phenylethylamine (PEA), benzylamine, and histamine. Both enzymes redundantly metabolize dopamine and dietary tyramine. Genetic variations altering the expression or enzymatic kinetics of both enzymes simultaneously create a severe compound bottleneck in peripheral and central monoamine clearance (Youdim et al., 2006).

The patient profile of compound homozygosity across three MAO-A single-nucleotide polymorphisms—rs1137070 (c.1460C>T), rs2072743, and rs66323 (c.882T>G)—alongside two MAO-B polymorphisms—rs1799836 (intron 13 A>G) and rs2283729—represents a complex multi-locus genotype. The rs1137070 T allele and rs66323 G variant significantly impair MAO-A transcriptional efficiency and catalytic turnover (Hotamisligil & Breakefield, 1991). Concurrently, homozygosity at MAO-B rs1799836 and rs2283729 leads to marked down-regulation of MAO-B protein synthesis and reduced enzymatic activity in peripheral tissues and brain astrocytes (Kakinuma et al., 2020; Magalhães et al., 2023).

When an individual carries homozygous low-activity variants across both *MAOA* and *MAOB* genes (located adjacent to each other on chromosome Xp11.3), dual-pathway clearance is severely compromised. Biogenic amines and dietary tyramine cannot be efficiently degraded in the gastrointestinal mucosa, liver, or vascular endothelium. This loss of enzymatic redundancy leads to sustained accumulation of serotonin, norepinephrine, dopamine, histamine, and tyramine in circulating blood and peripheral nerve terminals, triggering systemic neurovascular instability, chronic oxidative stress, and hypercoagulability.

Cardiovascular Manifestations and Systemic Disease Risks

The primary cardiovascular consequence of combined MAO-A and MAO-B low activity is severe adrenergic and serotonergic vascular hyper-reactivity. Elevated circulating norepinephrine and epinephrine induce persistent peripheral arterial vasoconstriction, leading to essential hypertension, labile blood pressure, and

paroxysmal hypertensive surges. Furthermore, ingested dietary tyramine bypasses degraded gut/hepatic clearance, directly releasing massive stores of norepinephrine from sympathetic nerve terminals—a phenomenon known as the "pressor reaction" or "tyramine crisis." **This manifests physically as sudden severe throbbing headaches, diaphoresis, palpitations, and dangerous acute hypertensive crises** (Youdim et al., 2006).

In addition to hypertension, excess circulating serotonin (5-HT) and catecholamines accelerate atherothrombosis and microvascular ischemia. Platelets store vast amounts of serotonin; in a hypofunctional MAO state, elevated plasma serotonin binds to platelet 5-HT2A receptors, promoting hyper-aggregation and microthrombus formation. Simultaneously, elevated monoamine oxidation by alternative pathways generates excess intracellular hydrogen peroxide (H2O2) and reactive oxygen species (ROS) within vascular endothelial cells, impairing nitric oxide availability, promoting endothelial dysfunction, and initiating coronary artery vasospasm and premature atherosclerosis (Sturza et al., 2013).

Beyond macrovascular disease, dual MAO-A/MAO-B impairment severely disrupts systemic histamine clearance and neurobehavioral homeostasis. Because MAO-B contributes significantly to peripheral histamine breakdown, homozygous loss of MAO-B function—compounded by MAO-A suppression—causes systemic histamine intolerance. Patients present with recurring flushing, dermatographism, urticaria, bronchospasm, gastrointestinal dysmotility (cramping, diarrhea), and refractory migraines. Central monoamine overload impairs emotional regulation, triggering chronic anxiety, panic disorders, sleep architectural disruption (severe insomnia), dysautonomia, and heightened pain sensitivity (Magalhães et al., 2023).

Conventional Pharmacotherapy, Biologicals, and Clinical Trade-offs

Clinical management of combined MAO-A/MAO-B low activity focuses on blunting catecholamine surges, controlling amine-mediated vascular activation, and mitigating thrombotic risks.

Therapy / Intervention	Drug Class & Mechanism	Clinical Effectiveness	Estimated Monthly Cost	Key Side Effects & Risks
Low-Dose Aspirin (81 mg/day)	Antiplatelet / COX-1 Inhibitor; blocks thromboxane A2 and serotonin-amplified platelet aggregation.	High in preventing amine-driven arterial microthrombosis and vascular events.	$5 – $15	Dyspepsia, gastric mucosal ulceration, GI bleeding, frequent patient refusal.
Alpha-1 & Beta-Blockers (e.g.,	Combined Sympatholytic Antagonist; blocks peripheral alpha-1	Superior efficacy in blunting hypertensive spikes and	$15 – $40	Bradycardia, orthostatic hypotension, fatigue,

Therapy / Intervention	Drug Class & Mechanism	Clinical Effectiveness	Estimated Monthly Cost	Key Side Effects & Risks
Labetalol, Carvedilol)	vasoconstriction and beta-1 cardiac activation.	tachyarrhythmias from catecholamine surges.		bronchospasm in asthmatics.
H1/H2 Receptor Antagonists (e.g., Cetirizine + Famotidine)	Histamine Antagonists; blocks peripheral H1 (vascular/skin) and H2 (cardiac/GI) histamine signaling.	Highly effective in suppressing MAO-B-mediated histamine flare-ups and flushing.	$10 – $30	Sedation, dry mouth, urinary retention, anticholinergic side effects.
CGRP Inhibitors / Monoclonal Antibodies (e.g., Erenumab)	Biological Neuromodulator; neutralizes calcitonin gene-related peptide involved in amine-triggered neurovascular inflammation.	High efficacy in preventing refractory neurovascular migraines and vasospasms.	$600 – $1,200	Injection site reactions, severe constipation, transient hypertension spikes.
Anti-IgE Biologicals (e.g., Omalizumab)	Biological Monoclonal Antibody; binds circulating IgE to downregulate mast cell degranulation.	Moderate to High in severe, refractory histamine/mast cell activation syndrome (MCAS).	$1,200 – $3,000	Anaphylaxis risk, arthralgia, upper respiratory infections, high financial barrier.

While low-dose aspirin remains a standard preventive antiplatelet agent against monoamine-mediated microthrombosis, it fails to alter upstream amine accumulation or endothelial oxidative damage. Furthermore, many patients refuse aspirin due to bleeding risks or gastrointestinal intolerance. Notably, central-acting monoamine reuptake inhibitors (SSRIs, SNRIs) and exogenous sympathomimetic agents are strictly contraindicated in these patients due to the high risk of precipitating serotonin syndrome or fatal hypertensive crisis.

Stand-Alone Natural Protocols for Aspirin-Refusive Patients

For patients with combined MAO-A and MAO-B double homozygosity who refuse baby aspirin and require non-pharmaceutical alternatives, therapeutic management must address dietary amine restriction, systemic enzymatic clearance, and intracellular redox protection.

1. Low-Amine (Tyramine & Histamine) Nutritional Strategy

The foundational intervention involves a strict low-tyramine and low-histamine diet. Patients must eliminate aged cheeses, fermented soy, cured meats, wine, aged fish, leftovers, and cultured foods. Reducing exogenous monoamine intake prevents the gut-derived pressor response and drastically reduces the metabolic burden on residual MAO enzymes, lowering baseline blood pressure and vascular reactivity.

2. Natural Fibrinolytic and Antiplatelet Protection

To replace aspirin's anti-thrombotic properties, natural systemic fibrinolytic enzymes—specifically **Nattokinase** (10,000 FU daily) or **Lumbrokinase**—are introduced. Nattokinase directly cleaves intravascular fibrin, downregulates PAI-1, and blunts serotonin-induced platelet hyperactivity without causing gastric mucosal ulceration. Combining systemic enzymes with high-concentration **Omega-3 Fatty Acids (EPA/DHA)** and bioavailable **Curcumin** inhibits COX-1/COX-2 pathways and downregulates endothelial cell adhesion molecules, matching aspirin's vascular protective benefits.

3. Cofactor Support & Histamine Clearance Optimization

Both MAO-A and MAO-B rely on flavin adenine dinucleotide (FAD), derived directly from **Riboflavin (Vitamin B2)**. High-dose Riboflavin supplementation (100–400 mg daily) optimizes the catalytic turnover of residual MAO enzyme proteins. To manage MAO-B-related histamine accumulation, supplemental **Diamine Oxidase (DAO)** enzymes taken before meals break down intestinal histamine, while **Quercetin** stabilizes mast cells to prevent endogenous histamine release.

4. Intracellular Redox Preservation (The VARS Triad)

The oxidation of biogenic amines by residual enzymatic pathways and secondary oxidative routes generates significant hydrogen peroxide (H_2O_2) and endothelial reactive oxygen species (ROS). The VARS Triad—utilizing Validated, Absorbable, Reduced, and Stable formulations of **Glutathione, Superoxide Dismutase (SOD), and Catalase**—provides targeted intracellular antioxidant defense. SOD dismutes superoxide radicals into hydrogen peroxide, which Catalase immediately degrades into water and oxygen. Reduced Glutathione quenches residual hydroperoxides and blocks NF-κB-driven endothelial cell inflammation. By neutralizing monoamine-derived oxidative stress, the VARS Triad shields the vascular endothelium from injury and vascular remodeling in patients seeking natural stand-alone protection.

References

Hotamisligil, G. S., & Breakefield, X. O. (1991). Human monoamine oxidase A gene determines levels of enzyme activity. *American Journal of Human Genetics*, *49*(2), 383–392.

Kakinuma, S., Beppu, M., Sawai, S., Nakayama, A., Hirano, S., Yamanaka, Y., Yamamoto, T., Masafumi, C., Aisihaer, X., Aersilan, A., Gao, Y., Sato, K., Sakae, I., Ishige, T., Nishimura, M., Matsushita, K., Satoh, M., & Nomura, F. (2020). Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. *Parkinsonism & Related Disorders*, *74*, 58–63. https://doi.org/10.1016/j.parkreldis.2020.04.004

Magalhães, P. V., Kapczinski, F., & Nardin, P. (2023). Individual and combined effect of MAO-A/MAO-B gene variants on stress response and biogenic amine metabolism. *Behavioral Sciences*, *13*(10), Article 795. https://doi.org/10.3390/bs1310795

Sturza, A., Leisegang, M. S., Nandorfy, P. M., Pflüger, B., Duerrschmid, N., Brandes, R. P., & Szöcs, K. (2013). Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. *Hypertension*, *62*(1), 140–146. https://doi.org/10.1161/HYPERTENSIONAHA.113.01314

Youdim, M. B., Edmondson, D., & Tipton, K. F. (2006). The therapeutic potential of monoamine oxidase inhibitors. *Nature Reviews Neuroscience*, *7*(4), 295–309. https://doi.org/10.1038/nrn1883